News and updates

Viewing:

All Years 2023 2022 2021 & Older

December 5, 2023

Curia Recognized on India Pharma Outlook’s 2023 List of Top 10 CDMO Companies in India

Curia recognized as one of the top 10 CDMOs in India acknowledging the contributions of Curia’s Aurangabad and Hyderabad sites.

September 15, 2023

Curia Supports Replicate Bioscience’s Phase 1 Clinical Trial of Novel Next-Generation RNA Vaccine

Supply of drug substance manufactured under cGMP supports first-in-human clinical study for RBI-4000 novel self-replicating RNA (srRNA)

July 24, 2023

Curia expands biologics capabilities with access to Touchlight’s doggybone DNA

Curia collaborates with Touchlight to expand its mRNA manufacturing offering to enable access to enzymatic doggybone DNA (dbDNA™)

June 29, 2023

Curia wins 2023 Frost & Sullivan Customer Value Leadership Award

Curia recognized for providing a best-in-class customer experience in the CRDMO industry through its innovative approach and growth strategy

June 20, 2023

Curia Expands Cell Line Development Offering with CHOZN Platform

Curia signs license agreement with MilliporeSigma to support production of proteins and antibodies

March 23, 2023

Curia Collaborates with Corning to Advance Biopharmaceutical Continuous-Flow Development and Manufacturing Programs

Collaboration marks the first global installation of Corning’s G1 production system to support higher-quality API-chemical production using inherently safer flow-chemistry technology

March 16, 2023

Curia Appoints Philip Macnabb as Chief Executive Officer

Philip Macnabb has been appointed as chief executive officer, succeeding John Ratliff. Macnabb joins Curia having spent years in leadership roles at various companies in the healthcare industry.

Ready to move from idea to impact?

Whether you have a question for our team or an opportunity you’re eager to pursue, one of our experts can help you get started.

Get started